Kolexia
Merle Philippe Gastro-entérologie
Merle Philippe
Gastro-entérologie
Hôpital La Croix-Rousse
Lyon, France
264 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome hépatocellulaire Carcinomes Tumeurs du foie Hépatite Hépatite B Maladies du foie Récidive tumorale locale Cirrhose du foie Hépatite C

Collaborateurs

Voir plus
Blanc Jean-Frederic
Blanc Jean-Frederic
Hôpital Saint-André, Bordeaux, France
Edeline Julien
Edeline Julien
Centre Eugène Marquis, Rennes, France
Assenat Eric
Assenat Eric
Icm Montpellier, Montpellier, France
Decaens Thomas
Decaens Thomas
Hôpital Nord Grenoble, La Tronche, France

Industries

Voir plus
Ipsen
36 collaboration(s)
Dernière en 2023
Roche
26 collaboration(s)
Dernière en 2023
AstraZeneca
20 collaboration(s)
Dernière en 2023
Bayer
16 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
COSMIC-312: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Essai Clinique (Exelixis)   20 mars 2024
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
Essai Clinique (BMS)   15 mars 2024
Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma.
Liver international : official journal of the International Association for the Study of the Liver   04 mars 2024
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
The lancet. Gastroenterology & hepatology   13 février 2024
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002): A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002)
Essai Clinique (Merck & Co.)   05 janvier 2024
STARHE: Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients
Essai Clinique (Institut Hospitalo Universitaire - Méditerranée Infection)   12 décembre 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
The Lancet. Oncology   04 décembre 2023
SOMAPROTECT01: Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma: Multicenter Randomized Double-blind Placebo Controlled Trial (SOMAPROTECT01)
Essai Clinique (Hospices Civils de Lyon)   27 novembre 2023
HESTIA: A Multicentric National Phase II Trial Assessing TIslelizumab in Monotherapy for Patients With Hepatocellular Carcinoma Child-Pugh B and ALBI Grade 1 or 2 Liver Function Score
Essai Clinique (Unicancer)   06 novembre 2023
IMbrave150: A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Essai Clinique (Roche)   05 octobre 2023